ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 40211406

Immunotherapy in chronic lymphocytic leukemia: advances and challenges.

Gao P and 3 others. Exp Hematol Oncol, 2025. Cited by 4 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Immunotherapy in chronic lymphocytic leukemia: advances and challenges. Papers, record 40211406. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40211406

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunotherapy in chronic lymphocytic leukemia: advances and challenges.
PubMed
Journal
Exp Hematol Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-04-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gao PPan
2Zhang YYang
3Ma JJun
4Zhang YYa

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82000195National Natural Science FoundationPubMed
2022M721981China Postdoctoral Science FoundationPubMed
tsqn201909184Taishan Scholars Program of Shandong ProvincePubMed
2020RC007Academic Promotion Programme of Shandong First Medical UniversityPubMed
ZR2024MH050, ZR2020QH094Shandong Provincial Natural Science FoundationPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References197

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115,172,969Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.Blood2004https://conductscience.org/library/papers/15172969PubMed
236,264,591Optimized CD19/CD22/CD3 antibody.Blood2022https://conductscience.org/library/papers/36264591PubMed
325,972,002Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.Sci Transl Med2015https://conductscience.org/library/papers/25972002PubMed
439,726,591TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC.Front Immunol2024https://conductscience.org/library/papers/39726591PubMed
528,983,798Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Adv Ther2017https://conductscience.org/library/papers/28983798PubMed
623,863,052Clinical practice: Herpes zoster.N Engl J Med2013https://conductscience.org/library/papers/23863052PubMed
738,238,616Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.Nat Med2024https://conductscience.org/library/papers/38238616PubMed
828,821,272Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.J Hematol Oncol2017https://conductscience.org/library/papers/28821272PubMed
938,987,565Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions.Cell Death Discov2024https://conductscience.org/library/papers/38987565PubMed
1039,966,627Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.Nat Rev Clin Oncol2025https://conductscience.org/library/papers/39966627PubMed

1 to 10 of 197

See all 197 references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42,389,542Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation.Front Immunol2026https://conductscience.org/library/papers/42389542PubMed
42,355,651Refractory Thrombocytopenia in TP53-Aberrant Chronic Lymphocytic Leukemia: A Multimechanistic Case with Response to Idelalisib and Romiplostim.J Clin Med2026https://conductscience.org/library/papers/42355651PubMed
41,902,977Investigating autophagy and miRNAs as therapeutic targets in leukemia.Discov Oncol2026https://conductscience.org/library/papers/41902977PubMed
41,303,291The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.J Clin Med2025https://conductscience.org/library/papers/41303291PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40211406

GET https://conductscience.org/api/papers/v1/40211406/references?page=2

API referenceFor AI assistants